APPENDIX A

Marked-up amended claims

24. (Amended) An isolated [PRO-C-MG.2, PRO-C-MG.12, PRO-C-MG.45, PRO-C-MG.64 or PRO-C-MG.72]polypeptide comprising an amino acid sequence [comprising] having at least about 80% sequence identity to the sequence of amino acid residues from about 1 to about 577 of SEQ ID NO:2[, about 1 to about 474 of SEQ ID NO: 4, about 1 to about 506 of SEQ ID NO: 18, about 1 to about 344 of SEQ ID NO: 16, or about 1 to about 633 of SEQ ID NO: 14, respectively].

25. (Amended) The isolated [PRO-C-MG.2, PRO-C-MG.12, PRO-C-MG.45, PRO-C-MG.64 or PRO-C-MG.72]polypeptide of Claim 24 comprising amino acid residues about 1 to about 577 of SEQ ID NO:2[, about 1 to about 474 of SEQ ID NO: 4, about 1 to about 506 of SEQ ID NO: 18, about 1 to about 344 of SEQ ID NO: 16, or about 1 to about 633 of SEQ ID NO: 14, respectively].

26. (Amended) An isolated [PRO-C-MG.2, PRO-C-MG.12, PRO-C-MG.45, PRO-C-MG.64 or PRO-C-MG.72]polypeptide having at least about 80% sequence identity to the polypeptide encoded by the cDNA insert of the vector deposited with the ATCC[on September 28, 1999, under ATCC] as Deposit No. PTA-799[, on September 28, 1999, under ATCC Deposit No. PTA-798, (DNA-C-MG.2-1776 and DNA-C-MG.12-1776, respectively)].

27. (Amended) The isolated [PRO-C-MG.2, PRO-C-MG.12, PRO-C-MG.45, PRO-C-MG.64 or PRO-C-MG.72] polypeptide of Claim 26 which is encoded by the cDNA insert of the vector deposited with the ATCC[on September 28, 1999, under ATCC] as Deposit No. PTA-799[, on September 28, 1999, under ATCC Deposit No. PTA-798, (DNA-C-MG.2-1776 and DNA-C-MG.12-1776, respectively)].

28. (Amended) An isolated [PRO-C-MG.2, PRO-C-MG.12, PRO-C-MG.45, PRO-C-MG.64 or PRO-C-MG.72]polypeptide scoring at least 80% positives when compared to the sequence of amino acid residues from about 1 to about 577 of SEQ ID NO:2[, about 1 to about 474 of SEQ ID NO: 4, about 1 to about 506 of SEQ ID NO: 18, about 1 to about 344 of SEQ ID NO: 16, or about 1 to about 633 of SEQ ID NO: 14, respectively].

29. (Amended) An isolated [PRO-C-MG.2, PRO-C-MG.12, PRO-C-MG.45, PRO-C-MG.64 or PRO-C-MG.72]polypeptide comprising the sequence of amino acid residues from about 1 to about 577 of SEQ ID NO:2[, about 1 to about 474 of SEQ ID NO: 4, about 1 to about 506 of SEQ ID NO: 18, about 1 to about 344 of SEQ ID NO: 16, or about 1 to about 633 of SEQ ID NO: 14, respectively], or a fragment [thereof]of the polypeptide sufficient to provide [a] binding [site for an anti-PRO-C-MG.2, PRO-C-MG.12, PRO-C-MG.45, PRO-C-MG.64 or PRO-C-MG.72 antibody]for an antibody capable of specifically binding to said isolated polypeptide.

30. (Amended) An isolated polypeptide produced by a method comprising [(i) hybridizing a test DNA molecule under stringent conditions with (a) a DNA molecule encoding a PRO-C-MG.2, PRO-C-MG.12, PRO-C-MG.45, PRO-C-MG.64 or PRO-C-MG.72 polypeptide comprising the sequence of amino acid residues from about 1 to about 577 of SEQ ID NO:2, about 1 to about 474 of SEQ ID NO: 4, about 1 to about 506 of SEQ ID NO: 18, about 1 to about 344 of SEQ ID NO: 16, or about 1 to about 633 of SEQ ID NO: 14, respectively, or (b) the complement of the DNA molecule of (a), (ii)] (i) culturing a host cell comprising[the test] a DNA molecule under conditions suitable for [the] expression of the polypeptide, wherein said DNA molecule is capable of hyrbirdzing under stringent conditions with (a) a DNA molecule encoding a polypeptide comprising the sequence of amino acid residues from about 1 to about 577 of SEQ ID NO:2, or (b) the complement of the DNA molecule of (a); and[(iii)] (ii) recovering the polypeptide from the cell culture.

32. (Amended) A chimeric molecule comprising a [PRO-C-MG.2, PRO-C-MG.12, PRO-C-MG.45, PRO-C-MG.64 or PRO-C-MG.72]polypeptide of SEQ ID NO:2 fused to a heterologous amino acid sequence.

60. (Amended) A composition comprising[(a)] a [PRO-C-MG.2, PRO-C-MG.12, PRO-C-MG.45, PRO-C-MG.64 or PRO-C-MG.72]polypeptide of SEQ ID NO:2[, (b) an agonist to a PRO-C-MG.2, PRO-C-MG.12, PRO-C-MG.45, PRO-C-MG.64 or PRO-C-MG.72 polypeptide, (c) an antagonist to a PRO-C-MG.2, PRO-C-MG.12, PRO-C-MG.45, PRO-C-MG.64 or PRO-C-MG.72 polypeptide, or (d) an anti-PRO-C-MG.2, PRO-C-MG.12, PRO-C-

MG.45, PRO-C-MG.64 or PRO-C-MG.72 antibody] in admixture with a pharmaceutically acceptable carrier.

61. (Amended) The composition of Claim 60 comprising a therapeutically effective amount of [(a) aPRO-C-MG.2, PRO-C-MG.12, PRO-C-MG.45, PRO-C-MG.64 or PRO-C-MG.72]a polypeptide of SEQ ID NO:2[, (b) an agonist of a PRO-C-MG.2, PRO-C-MG.12, PRO-C-MG.45, PRO-C-MG.64 or PRO-C-MG.72 polypeptide, or (c) an antagonist of a PRO-C-MG.2, PRO-C-MG.12, PRO-C-MG.45, PRO-C-MG.64 or PRO-C-MG.72 polypeptide, thereof].

67. (Amended) A method of preparing the composition of Claim 60 comprising admixing[(a)] a [PRO-C-MG.2, PRO-C-MG.12, PRO-C-MG.45, PRO-C-MG.64 or PRO-C-MG.72]polypeptide of SEQ ID NO:2[, (b) an agonist of a PRO-C-MG.2, PRO-C-MG.12, PRO-C-MG.45, PRO-C-MG.64 or PRO-C-MG.72 polypeptide, or (c) an antagonist of a PRO-C-MG.2, PRO-C-MG.12, PRO-C-MG.45, PRO-C-MG.64 or PRO-C-MG.72 polypeptide,] with a pharmaceutically acceptable carrier.

APPENDIX B

Clean set of present and pending claims

24. (Amended) An isolated polypeptide comprising an amino acid sequence having at least about 80% sequence identity to the sequence of amino acid residues from about 1 to about 577 of SEQ ID NO:2.

25. (Amended) The isolated polypeptide of Claim 24 comprising amino acid residues about 1 to about 577 of SEQ ID NO:2.

26. (Amended) An isolated polypeptide having at least about 80% sequence identity to the polypeptide encoded by the cDNA insert of the vector deposited with the ATCC as Deposit No. PTA-799.

27. (Amended) The isolated polypeptide of Claim 26 which is encoded by the cDNA insert of the vector deposited with the ATCC as Deposit No. PTA-799.

28. (Amended) An isolated polypeptide scoring at least 80% positives when compared to the sequence of amino acid residues from about 1 to about 577 of SEQ ID NO:2.

29. (Amended) An isolated polypeptide comprising the sequence of amino acid residues from about 1 to about 577 of SEQ ID NO:2, or a fragment of the polypeptide sufficient to provide binding for an antibody capable of specifically binding to said isolated polypeptide.

30. (Amended) An isolated polypeptide produced by a method comprising (i) culturing a host cell comprising a DNA molecule under conditions suitable for expression of the polypeptide, wherein said DNA molecule is capable of hybridizing under stringent conditions with (a) a DNA molecule encoding a polypeptide comprising the sequence of amino acid residues from about 1 to about 577 of SEQ ID NO:2, or (b) the complement of the DNA molecule of (a); and (ii) recovering the polypeptide from the cell culture.

31. The isolated polypeptide of Claim 30, wherein the test DNA has at least about 80% sequence identity to (a) or (b).

32. (Amended) A chimeric molecule comprising a polypeptide of SEQ ID NO:2 fused to a heterologous amino acid sequence.

33. The chimeric molecule of Claim 32, wherein the heterologous amino acid sequence is an epitope tag sequence.

34. The chimeric molecule of claim 32, wherein the heterologous amino acid sequence is a secretion signal peptide.

35. The chimeric molecule of Claim 32, wherein the heterologous amino acid sequence is a Fc region of an immunoglobulin.

60. (Amended) A composition comprising a polypeptide of SEQ ID NO:2 in admixture with a pharmaceutically acceptable carrier.

61. (Amended) The composition of Claim 60 comprising a therapeutically effective amount of a polypeptide of SEQ ID NO:2.

62. The composition of Claim 60, further comprising a cardiovascular, endothelial, angiogenic, or angiostatic agent.

67. (Amended) A method of preparing the composition of Claim 60 comprising admixing a polypeptide of SEQ ID NO:2 with a pharmaceutically acceptable carrier.